Replies to post #6908 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Silver, I think the patents had already been assigned to AbbVie in the fall of 2016 and that is why the posted patent application on the USPTO site does not display the assignee.

They have the patents covering TRT and HSDD for now and are working on the CV and Breast Cancer related patents.

I believe that AbbVie is looking to get Libigel to market as they face Humira biosimilar competition in Europe October 2018. Some countries are starting to mandate starting patients off less expensive biosimilars before moving to the branded drug. Investors believe Humira may be safe in the US for a while. But I wouldn't count on it. It looks like BI is using a similar approach that proved successful in the UK challenging the novelty of the patents that were issued.

I feel the deal is already in place. The formal process is now finalizing the details filing withe SEC and submitting it to a vote. Don't be surprised if the FDA already has received the minimum 90 day notice for the intention to use the PRV.